Memantine for Liver Cancer

Phase 2 & 3

Recruiting

Led By Arthur Winer, MD

Research Sponsored by Inova Health Care Services

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years from the initial visit

Awards & highlights

No Placebo-Only Group

Summary

This trial looks at the effects of a single med, memantine, on people with advanced liver cancer who cannot have other treatments. We'll measure effects on quality of life too.

Who is the study for?

This trial is for adults over 18 with advanced, inoperable liver cancer (hepatocellular carcinoma) who haven't had intensive systemic therapy. They must have a specific level of cirrhosis (Child-Pugh score B7+), be able to perform daily activities with minimal help, and agree to use contraception if there's any chance of pregnancy.

What is being tested?

The study tests the drug Memantine (Namenda) on patients with liver cancer that can't be removed by surgery. It aims to see how effective the drug is and its impact on quality of life over time. Participants will receive Memantine as a single agent treatment.

What are the potential side effects?

While not specified here, common side effects of Namenda may include dizziness, headache, confusion, constipation. Since it's being tested in people with liver issues, monitoring for worsening liver function or other organ-related problems would also be important.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years from the initial visit

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years from the initial visit

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years from the initial visit for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Patients Progression Free Survival at 6 months

Other study objectives

Change from baseline as assessed by the European Organization for Research and Treatment of Cancer (EORTC) quality-of-life questionnaire for cancer (EORTC QLQ-C30)

Change from baseline as assessed by the European Organization for Research and Treatment of Cancer (EORTC-HCC18) over treatment